Abbvie, obesity and Gubra

Abbvie enters $2.2B deal for Gubra’s amylin obesity drug
Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with Danish peptide drug discovery specialist Gubra A/S. In addition, there will be a $350 million up-front payment as Abbvie takes over the reins of GUB-014295 (referred to as Gubamy),
AbbVie enters obesity drug market with up to $2.2 billion Gubra deal
The licensing deal could set the US drugmaker to vie with Eli Lilly & Co. and Novo Nordisk A/S, the current leaders in a market that's expected to reach $130 billion in annual sales by 2030
AbbVie, Gubra in Obesity-Drug License Pact Potentially Worth More Than $2 Billion
AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services company.
AbbVie steps into the obesity drug race, licensing medicine from Danish firm
The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
AbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s experimental obesity drug, GUB014295. This marks the American drugmaker’s foray into the lucrative obesity market.
AbbVie Inc. (ABBV): Among the Best S&P 500 Dividend Stocks to Buy Now
We recently compiled a list of the 15 Best S&P 500 Dividend Stocks to Buy Now. In this article, we are going to take a look ...
Insiders At AbbVie Sold US$23m In Stock, Alluding To Potential Weakness
Over the past year, many AbbVie Inc. insiders sold a significant stake in the company which may have piqued investors' ...
AbbVie Inc. (NYSE:ABBV) Receives Average Recommendation of “Moderate Buy” from Brokerages
Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ...
AbbVie Inc. (ABBV): Among the Best Psychedelic Stocks to Buy in 2025
We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...
AbbVie Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
AbbVie (NYSE:ABBV) Reaches New 12-Month High – What’s Next?
AbbVie Inc. (NYSE:ABBV – Get Free Report) shares hit a new 52-week high on Friday . The company traded as high as $207.42 and ...
stocknews4d
3 Healthcare Stocks Tackling America’s Biggest Medical Challenges
From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare ...
American Association of Individual Investors11d
Which Is a Better Investment, AbbVie Inc. or BeiGene, Ltd. Stock?
Learn more about whether AbbVie Inc. or BeiGene, Ltd. is a better investment based on AAII's A+ Investor grades, which ...
Yahoo Finance8d
AbbVie Inc. (ABBV): Among S&P 500 Dividend Aristocrats List
In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other S&P 500 dividend aristocrats sorted by hedge fund sentiment. Dividend Aristocrats are companies ...
AbbVie Inc. stock underperforms Monday when compared to competitors despite daily gains
This was the stock's third consecutive day of gains.